Weight Loss Drugs Threaten $55B in Food Sales, Spur Industry Shift

GLP-1 Medications Reshape Restaurant and Food Industry Strategies

The growing adoption of GLP-1 drugs, like Ozempic and Zepbound, initially developed for type 2 diabetes management, is forcing a strategic reassessment across the restaurant and packaged food industries. Approximately one in eight U.S. Adults are currently taking a GLP-1 drug, according to a November poll by KFF Health Tracking Poll, a figure that doesn’t even account for those who have previously used the medications. These drugs, which slow digestion and suppress appetite, are leading to shifts in consumer behavior – notably, reduced calorie consumption and decreased spending on groceries – and prompting businesses to adapt or risk significant sales declines. JPMorgan estimates the growing use of these medications could wipe out $30 billion to $55 billion in annual sales for the food and beverage industry as soon as 2030.

The Impact on Consumer Spending

The core effect of GLP-1s is a reduction in overall food intake. KPMG data indicates that adults using these drugs consume 21% fewer calories on average and spend nearly a third less on grocery bills. This trend is particularly noticeable in snacking, with 70% of GLP-1 users reporting they are snacking less, according to a survey conducted by EY-Parthenon last spring. The shift isn’t uniform, however; consumers are increasingly opting for healthier snack options like yogurt, nuts, and fruit, rather than chips or pretzels. This change in behavior extends to dining out, with 60% of EY-Parthenon survey respondents reporting less frequent restaurant visits. Even alcohol consumption is declining, with roughly 45% of those eating and drinking less also drinking less alcohol.

Restaurant Responses: Smaller Portions and Protein Focus

Restaurants are beginning to respond to these changing consumer habits. Clinton Hall, for example, has introduced a “Teeny Weeny Mini Meal” – a smaller-sized version of its regular burger, fries, and beer combo – catering to those with reduced appetites. More broadly, the industry is exploring strategies like labeling menu items as “GLP-1 friendly,” decreasing portion sizes, and emphasizing protein content. Dana Baggett, executive director of restaurant client strategy at RRD, notes that lunch traffic hasn’t been significantly impacted yet, but breakfast has seen a decline, particularly among higher-income GLP-1 users. Starbucks’ protein cold foam options are one example of a potential draw for this demographic.

Dinner and Fast Food Face the Biggest Challenges

The impact of GLP-1s is most pronounced on dinner traffic, particularly at fast-food restaurants. According to RRD data, dinner traffic has fallen 6% among consumers regularly taking GLP-1 medications, representing a 0.4% overall decline in restaurant sales during dinner hours. For limited-service restaurants like McDonald’s and Taco Bell, where snacking accounts for 12% of spending (according to Bank of America Global Research), the potential for revenue loss is significant. However, industry observers like Baggett caution against panic, emphasizing that this is an opportunity for brands to reposition themselves by focusing on healthier options, higher protein content, and fiber.

Big Food Adapts: Protein, Fiber, and Portion Control

Major food companies are also adjusting their strategies. PepsiCo, for instance, has launched protein-packed Doritos and fiber-rich varieties of SunChips and Smartfood popcorn. Nestle launched Virtual Pursuit, a frozen-food brand targeting GLP-1 users, and later updated its packaging to prominently feature the “GLP-1 friendly” designation. Nestle CEO Marty Thompson indicated the company plans to expand into protein-rich beverages, like shakes. Domino’s Pizza CEO Russell Weiner stated the chain hasn’t yet seen an impact on sales but is prepared to innovate its menu if necessary. Chipotle launched grab-and-move protein cups in December, while Olive Garden, owned by Darden Restaurants, introduced a Lighter Portions menu last year, downsizing entrees at a lower price point. J&J Snack Foods, owner of Dippin’ Dots and Icee, is experimenting with smaller portion sizes and formulations with added protein, and antioxidants.

The Oral Pill and Future Adoption

The recent launch of oral GLP-1 medications, like Novo Nordisk’s Wegovy pill and the upcoming release from Eli Lilly, is expected to accelerate adoption. J.P. Morgan estimates that more than 30 million Americans could be on a GLP-1 treatment by 2030, up from 10 million in 2026. However, the long-term impact remains uncertain. Approximately 5% of GLP-1 users eventually discontinue use due to cost, side effects, or achieving their weight loss goals, and their eating habits may revert over time. The oral pill may attract a new segment of users who were previously hesitant to use injections.

Navigating a Shifting Landscape

The restaurant and food industries are entering a period of significant change. While the full extent of the impact from GLP-1 medications remains to be seen, the initial data suggests a need for adaptation. Companies that proactively adjust their menus, portion sizes, and marketing strategies to appeal to this growing segment of health-conscious consumers are likely to be best positioned for success. The key will be balancing innovation with broader consumer preferences and recognizing that the landscape is still evolving as more data emerges on long-term usage patterns and the impact of oral medications.

Looking Ahead: The industry will be closely monitoring sales data and consumer behavior in the coming quarters to refine their strategies. Earnings calls and investor presentations will provide valuable insights into how companies are navigating this evolving market. Further research into the impact of oral GLP-1 medications will be crucial for understanding the long-term implications for the food and beverage sector.